- Home
- VNDA vs FDMT Comparison
VNDA vs FDMT Comparison
Compare VNDA & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VNDA
- FDMT
- Stock Information
- Founded
- VNDA 2002
- FDMT 2013
- Country
- VNDA United States
- FDMT United States
- Employees
- VNDA N/A
- FDMT N/A
- Industry
- VNDA Biotechnology: Pharmaceutical Preparations
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- VNDA Health Care
- FDMT Health Care
- Exchange
- VNDA Nasdaq
- FDMT Nasdaq
- Market Cap
- VNDA 282.8M
- FDMT 268.6M
- IPO Year
- VNDA 2006
- FDMT 2020
- Fundamental
- Price
- VNDA $4.99
- FDMT $3.82
- Analyst Decision
- VNDA Strong Buy
- FDMT Buy
- Analyst Count
- VNDA 2
- FDMT 10
- Target Price
- VNDA $16.50
- FDMT $35.00
- AVG Volume (30 Days)
- VNDA 673.5K
- FDMT 672.2K
- Earning Date
- VNDA 05-07-2025
- FDMT 05-08-2025
- Dividend Yield
- VNDA N/A
- FDMT N/A
- EPS Growth
- VNDA N/A
- FDMT N/A
- EPS
- VNDA N/A
- FDMT N/A
- Revenue
- VNDA $198,772,000.00
- FDMT $37,000.00
- Revenue This Year
- VNDA $14.36
- FDMT $11,029.73
- Revenue Next Year
- VNDA $44.53
- FDMT $44.15
- P/E Ratio
- VNDA N/A
- FDMT N/A
- Revenue Growth
- VNDA 3.18
- FDMT N/A
- 52 Week Low
- VNDA $3.71
- FDMT $3.73
- 52 Week High
- VNDA $6.75
- FDMT $36.25
- Technical
- Relative Strength Index (RSI)
- VNDA 57.32
- FDMT 36.09
- Support Level
- VNDA $4.84
- FDMT $3.73
- Resistance Level
- VNDA $5.16
- FDMT $4.44
- Average True Range (ATR)
- VNDA 0.23
- FDMT 0.36
- MACD
- VNDA 0.02
- FDMT 0.01
- Stochastic Oscillator
- VNDA 66.10
- FDMT 8.25
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.